Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) shares shot up 1.8% on Friday . The company traded as high as $22.08 and last traded at $21.74, with a volume of 164,682 shares trading hands. The stock had previously closed at $21.35.

A number of brokerages have weighed in on SUPN. Jefferies Group restated a “buy” rating and issued a $28.00 price objective (up previously from $23.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 4th. Zacks Investment Research lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Northland Securities lowered Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price objective on the stock. in a report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price objective on the stock. in a report on Monday, July 18th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $24.50.

The company has a market capitalization of $1.09 billion and a price-to-earnings ratio of 45.04. The stock has a 50 day moving average price of $22.00 and a 200 day moving average price of $17.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.05. During the same period in the previous year, the firm posted $0.03 EPS. The company earned $50.40 million during the quarter, compared to analyst estimates of $49.67 million. The company’s revenue for the quarter was up 43.6% on a year-over-year basis. On average, analysts anticipate that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current fiscal year.

In other news, CFO Gregory S. Patrick sold 3,395 shares of the business’s stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $22.00, for a total value of $74,690.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

An institutional investor recently bought a new position in Supernus Pharmaceuticals stock. Marshall Wace LLP acquired a new position in Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 174,513 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,345,000. Marshall Wace LLP owned about 0.36% of Supernus Pharmaceuticals as of its most recent SEC filing.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.